Update: Influenza Activity — United States and Worldwide, May 20–October 13, 2018

Eric J. Chow, MD; C. Todd Davis, PhD; Anwar Isa Abd Elal; Noreen Alabi, MPH; Eduardo Azziz-Baumgartner, MD; John Barnes, PhD; Lenee Blanton, MPH; Lynnette Brammer, MPH; Alicia P. Budd, MPH; Erin Burns, MA; William W. Davis, DrPH; Vivien G. Dugan, PhD; Alicia M. Fry, MD; Rebecca Garten, PhD; Lisa A. Grohskopf, MD; Larisa Gubareva, PhD; Yunho Jang, PhD; Joyce Jones, MS; Krista Kniss, MPH; Stephen Lindstrom, PhD; Desiree Mustaquim, MPH; Rachael Porter, MPH; Melissa Rolfes, PhD; Wendy Sessions, MPH; Calli Taylor, MPH; David E. Wentworth, PhD; Xiyan Xu, MD; Natosha Zanders, MS; Jacqueline Katz, PhD; Daniel Jernigan, MD


Morbidity and Mortality Weekly Report. 2018;67(42):1178-1185. 

In This Article

Antiviral Resistance of Influenza Viruses

The WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC tested 347 influenza virus specimens collected during May 20–October 13 from the United States and worldwide for resistance to oseltamivir, peramivir, and zanamivir, the influenza virus neuraminidase inhibitor antiviral medications currently approved for use against seasonal influenza. Among 134 influenza A(H1N1)pdm09 viruses (63 in and 71 outside the United States), 132 influenza A(H3N2) viruses (57 in and 75 outside the United States), and 81 influenza B viruses (44 in and 37 outside the United States) tested, all were susceptible to all three medications. High levels of resistance to the adamantanes (amantadine and rimantadine) persisted among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses, which is consistent with the current recommendation to avoid use of these medications against influenza at this time.§§§§